AXA Framlington Biotech Fund - R Income

Register to Unlock Ratings
Performance History30/09/2024
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech Fund - R Income
Fund31.42.33.01.13.8
+/-Cat5.511.410.92.45.1
+/-B’mrk-1.52.00.6-6.2-2.9
 
Key Stats
NAV
04/10/2024
 GBX 269.40
Day Change -1.89%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
30/08/2024
 GBP 432.07
Share Class Size (Mil)
04/10/2024
 GBP 23.96
Max Initial Charge -
Ongoing Charge
01/06/2024
  1.56%
Investment Objective: AXA Framlington Biotech Fund - R Income
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.
Returns
Trailing Returns (GBP)04/10/2024
YTD4.02
3 Years Annualised1.98
5 Years Annualised10.69
10 Years Annualised8.05
12 Month Yield 0.00
Management
Manager Name
Start Date
Chris Eccles
29/03/2024
Cinney Zhang
29/03/2024
Click here to see others
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech Fund - R Income31/08/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock97.580.0097.58
Bond0.000.000.00
Property0.000.000.00
Cash2.860.442.42
Other0.000.000.00
Top 5 Regions%
United States78.16
United Kingdom9.04
Europe - ex Euro7.17
Eurozone2.48
Asia - Emerging1.83
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare9.07
Vertex Pharmaceuticals IncHealthcareHealthcare7.81
Amgen IncHealthcareHealthcare6.59
AstraZeneca PLC ADRHealthcareHealthcare5.33
Alnylam Pharmaceuticals IncHealthcareHealthcare3.85
AXA Framlington Biotech Fund - R Income

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures